Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance ...

CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...

MELBOURNE, Australia & SAN DIEGO--(BUSINESS WIRE)--Akaal Pharma, a clinical-stage drug discovery and development company, today announced the publication of preclinical studies of safety and efficacy ...

Both biotechs have S1P1 receptor drugs, but they're not created equal. Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only ...

ENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies ...

SOUTH SAN FRANCISCO, Calif. & INGELHEIM, Germany -- May 7, 2009 - Exelixis, Inc. (Nasdaq: EXEL) and Boehringer Ingelheim, a global pharmaceutical group of companies, headquartered in Germany, ...

Taicang, Suzhou, July 30, 2015 – Suzhou Connect Biopharma announced today that it has successfully completed the single ascending dose study of its lead clinical candidate CBP-307 in healthy ...

While Ventyx Biosciences Inc.’s oral S1P1 receptor modulator, VTX-002, achieved primary and secondary endpoints in a phase II ulcerative colitis (UC) trial, the company’s shares (NASDAQ:VTYX) fell ...

Autobahn Therapeutics Inc. has disclosed fatty acid amide (FAAH) cleavable prodrugs acting as sphingosine 1-phosphate S1P1 receptor (S1PR1; EDG1) and/or S1P5 receptor (S1PR5; EDG8) agonists reported ...

What are G-protein coupled receptors (GPCRs) and what role do they play in the body? GPCRs are one of the largest families of cellular signalling proteins consisting of more than a thousand different ...

VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the team at Ventyx ENCINITAS, Calif., Dec. 06, ...